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Summary The motivation for proposing sequential methods for cancer clinical trials is presented, and the
methodology examined by re-analysing two completed phase III cancer trials of the Lung Cancer Working
Party of the British Medical Research Council. The reanalysis proceeds as if the trials had been designed with
a planned series of interim analyses governing stopping. Specifically, the triangular and double-triangular tests
were applied. The sequential reanalyses gave a substantial reduction in the number of patient required, and
deaths observed, for conclusions to be reached in comparison with the completed studies. In each case, the
sequential analysis was stratified for baseline prognostic factors which were seen to be important at the first
interim analysis.
A clinical trial in cancer is a scientific comparison of the
effectiveness of two or more treatments on a group of
patients whose disease is life threatening. As a result, the care
of the patients within the study is an important ethical issue.
Ethics and requirements of scientific precision may come into
conflict. A purely scientific view is as follows. From a
requirement specifying the power of the study to detect a
clinically important treatment difference, a target sample size
is fixed. This number of patients is recruited, treated and
followed up. When all of the data are complete, a statistical
analysis is performed and the significance and magnitude of
treatment differences are evaluated. Such a scheme is
scientifically valid, has good precision and corresponds to the
way in which investigations are conducted throughout
science. To care for the welfare of patients in a lengthy trial
of therapies with effects which are not fully understood, a
schedule of interim analyses is usually included at which the
evidence so far available on the safety and efficacy of the
experimental treatment is checked. If such an analysis reveals
early indications that the experimental treatment is harmful,
or that the benefits of the experimental treatment are now
established, then the trial may be stopped. It would be
unethical to continue randomisation of patients in these cir-
cumstances. However, the use of interim analyses gives the
investigators extra opportunities to discover apparent treat-
ment differences and the chance of erroneously claiming a
difference, the type I error rate, will increase. Furthermore,
when a trial has been stopped precisely because of the dis-
covery of a treatment difference, an estimate of the mag-
nitude of that difference will overstate its value. These effects
are well known, and have been described by Armitage,
McPherson and Rowe (1969).
An alternative form of clinical trial design can be used in
order partially to resolve the confficts between the need for a
precise scientific experiment and the need for compassionate
care of the patients included. Sequential designs for clinical
trials involve a planned series of interim analyses of the data,
conducted in a way which does not affect the fixed type I
error rate. These allow treatment groups to be compared
formally in respect of primary patient response, which in
cancer trials is often the survival time between commence-
ment of treatment and relapse or death. The result may be
that the study is stopped earlier than would be the situation
with a single analysis based on a fixed sample size, or that it
is continued for longer. Continuation will only occur when
the difference between treatments appears to be moderate. In
this situation, accurate estimation of its magnitude is
desirable. Many forms of sequential design are far more
likely to reduce the sample size than to increase it. At the end
of the trial, special methods of analysis have to be used as
conventional methods are invalid and would lead to bias.
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Sequential designs have been described at length by
Whitehead (1992a) and their application to cancer studies has
been discussed by Whitehead (1993). Earlier forms of sequen-
tial design were discussed by Armitage (1975) and alternative
approaches and views are given by Peto et al. (1976; Statis-
tical note 4), Peace (1992) and Machin (1992).
In this paper we present the results of reanalysing data
from two completed small cell lung cancer trials as if a
sequential design had been operated. The trials were con-
ducted by the Lung Cancer Working Party of the British
Medical Research Council. Our aim was to present two
trials, one ofwhich had found superiority of the experimental
treatment relative to control and another which had not. The
choice of these particular trials was limited by the facts that
only a few of the trials recently completed by the MRC
Cancer Office had demonstrated superiority and many of
them were designs comparing several treatments simul-
taneously. Although sequential procedures can be adapted to
multiple comparisons, there are a few unresolved issues, and
the methodology is most easily presented in terms of a two
treatment trial. Our intention was to evaluate the reduction
in sample size attained, and to compare conclusions drawn
from the reduced patient numbers with those actually
obtained from the full trials. Care was taken to select designs
which corresponded closely to the individual requirements of
the different trials. This contrasts with the approach taken by
Rosner and Tsiatis (1989) who reanalysed 72 cancer trials
conducted by the Eastern Cooperative Oncology Group in
the United States, applying the same battery of four sequen-
tial designs to each one. The designs chosen for our two
reanalyses were the double triangular test and the triangular
test respectively. These designs do not require the time inter-
vals between interim analyses, or the amount of new inform-
ation available for each, to be predetermined or of constant
size, as is the case for earlier group sequential designs such as
those of Pocock (1977) or O'Brien and Fleming (1979). This
flexibility is important even when interim analyses are
scheduled by the calendar, at 6 monthly intervals perhaps,
because the recruitment rate is likely to fluctuate resulting in
an uneven flow of information. The computer package
PEST3 (Brunier & Whitehead, 1993) allows these designs to
be evaluated and implemented with ease. The special analyses
needed after a sequential design are also provided. An alter-
native apparoach with comparable flexibility has been pro-
vided by Lan and DeMets (1983), and is known as the
a-spending function method in which the false-positive pro-
bability is used up according to a pre-specified rate.
Reanalysis of a clinical comparison of immediate
chemotherapy and radiotherapy vs selective treatment in the
management of small-cell lung cancer
In this trial, patients were allocated to one or other of two
treatment policies in a randomised procedure stratified for
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extent of disease and admitting centre. One policy was com-
bined chemotherapy and radiotherapy: patients were presc-
ribed immediate treatment with a four-drug chemotherapy
regimen including Etoposide, Cyclophosphamide, Methotrex-
ate and Viscristine (ECMV), planned to be given over six
courses at 3-week intervals, and patients with limited disease
were also given megavoltage radiotherapy (40 Gy) to the
loco-regional disease between the second and third courses of
chemotherapy. The other policy was designated SELECTIVE
TREATMENT (ST) in which appropriate treatment was
delayed until required symptomatically. Then either local
palliative radiotherapy or single-drug chemotherapy was
given as and when required to control symptoms (Medical
Research Council Lung Cancer Working Party, 1989a).
Resultsfrom the completed study
Between June 1981 and February 1985, a total of 76 eligible
patients were allocated to the combined chemotherapy and
radiotherapy group (ECMV) and 75 were allocated to the
selective treatment (ST) group. At 72 months (June, 1987),
follow-up to 24 months had been completed for all 151
patients. No justification for the trial size was included in the
original protocol.
The first part of Table I shows a summary of the deaths
observed by patient time since recruitment and by treatment
group. Prognosis is clearly poor regardless of treatment, but
the ECMV group does appear to have the better survival
outcome.
Cox's regression model (Cox, 1972) was used to investigate
the relationship between the survival times and possible prog-
nostic variables in the full data set. Cox's model is described
in more straightforward terms in chapter 13 of the recent
book by Altman (1991) and in the forthcoming book by
Collett (1994). The most important variable in predicting
survival time was found to be the extent of disease with two
levels: extensive or limited (P = 0.0001). General condition at
time of randomisation with two levels: excellent/good or
fair/poor/very poor, was also important (P = 0.0001). This
TableI Summary ofdeathsbypatient timeandbytreatmentgroupoin
the trial ofchemotherapy and radiotherapy vs selective treatment in the
management of small-cell lung cancer
ECMVgroup STgroup
Time interval Number Number Number Number
since deaths at risk deaths at risk
randomisation during at start of during at start of
(months) interval interval interval interval
( 0,6) 25 76 49 75
( 6,12) 28 51 20 26
(12,15) 8 23 3 6
(15,18) 3 15 0 3
(18,72) 9 12 2 3
Total deaths 73 74
First Interim Analysis (December 1982)
( 0,6) 10 37 18 37
( 6,12) 10 17 7 11
(12,15) 0 3 0 0
(15,18) 0 0 0 0
(18,72) 0 0 0 0
Total deaths 20 25
Second (andfinal) Interim Analysis (June 1983)
( 0,6) 16 47 26 47
( 6,12) 13 23 10 12
(12,15) 2 4 0 1
(15,18) 0 2 0 1
(18,72) 0 2 0 0
Total deaths 31 36
was assessed by the clinician at each attendance according to
a daily diary card that the patients had completed. No other
factors were found to be significant. Treatment group had a
significant effect on survival after adjustment for extent of
disease and general condition (P = 0.0001). These results
confirm those obtained by the Medical Research Council
Lung Cancer Working Party (1989a) using the same data set,
as would be expected.
The analysis also shows that the instantaneous risk of
death for a patient in the ECMV group was 0.43 times that
for a patient in the ST group with the same extent of disease
and general condition. That is, the hazard ratio (HR) for
ECMV relative to ST was estimated to be 0.43 (95%
confidence interval 0.30 to 0.61). This shows that the com-
bined ECMV policy prolonged survival time considerably.
Extensive disease and poor general condition were associated
with unfavourable prognosis. The median survival was 8
months in the ECMV group compared to 4 months in the ST
group.
Choice ofsequential design
Among the sequential designs appropriate for this trial, the
double triangular test was chosen on the basis of its sym-
metric power requirement and mimumum sample size con-
siderations. The former property can be explained as follows:
the test guarantees a high probability of detecting either
superiority or inferiority of the experimental treatment
relative to the control. This seemed appropriate in this lung
trial because it was comparing two policies of treatment,
both of which had their advocates in the UK. On the one
hand, the selective palliative treatment was favoured by some
clinicians who considered that immediate combination
ECMV treatment could not be justified because its higher
level of toxicity might produce treatment-related deaths. On
the other hand, one or other schedule of ECMV was the
most commonly accepted management for small-cell lung
cancer in order to reduce the risk of the early metastases
commonly associated with this cancer. Since ECMV was
being widely used, it was as important to prove its inferiority,
if it was associated with shorter survival, as it was to prove
its superiority if it was beneficial. In the former case, the
investigators would be in a position to recommend discon-
tinuation of its use. This symmetric requirement can be
contrasted with the asymmetric design chosen for the second
trial presented in this paper.
In this small-cell lung cancer trial it was desirable to stop
the trial early if either of the treatments appeared superior,
or if there was no difference between them. The latter
requirement was motivated by the toxicity of the ECMV. In
the case of a modest improvement due to ECMV, however,
the sequential design guaranteed a larger sample size, which
was then desirable to obtain a more reliable estimate of the
treatment effect. The double triangular test achieves these
requirements on sample size (see Whitehead, 1992b).
Although the number of patients is likely to be largest when
the treatment difference is modest, this number is usually
smaller than in the equivalent conventional fixed-sample
design. Indeed the double triangular test minimises these
largest sample sizes amongst tests of equal power.
The double triangular test was designed to detect a
difference between the treatments measured in terms of im-
provement in survival on ECMV compared with ST. Median
survival in the ST group was likely to be 4 months. The
analysis conducted by the MRC was performed when 147
deaths had accumulated. To find the equivalent sequential
trial, the usual sample size calculation was performed in
reverse. This trial has 90% chance of detecting a hazard ratio
(ECMV relative to ST) of HR = 0.586 as significant at the
5% level (two-sided alternative). Suppose that the trial had
been intended to detect an improvement from half of the
patients surviving beyond 4 months on ST to two-thirds
surviving beyond 4 months on ECMV. This corresponds to
the target hazard ratio of HR = 0.586 mentioned above.SIMULATED SEQUENTIAL ANALYSIS 1173
The accumulating evidence concerning the treatment
difference was summarised in terms of statistics Z and V
(Whitehead, 1992, Section 3.4; Whitehead, 1993). The values
of both Z and V change as the trial proceeds. At each
interim analysis, the value of Z is plotted against that of V
and the boundaries illustrated in Figure la are used to
govern stopping. The statistic Z is a modification of the
log-rank statistic, allowing for stratification and prognostic
factors, which provides a cumulative measure of the evidence
of advantage of ECMV observed. The statistic V measures
the amount of information contained in the data about the
treatment effect, and it is roughly equal to one quarter of the
number of deaths which would have occurred at that point.
If at the design stage a recruitment rate of 3.2 patients per
month had been anticipated and the expected 4-month sur-
vival probabilities had been extrapolated exponentially, the
flow of information (denoted by V) over calendar time would
have been as shown in Table II. In particular, the 147 deaths
required for a fixed-sample study would have accrued in 60
months with 192 patients recruited. However, the MRC
Lung Cancer Working Party actually stopped recruitment at
45 months with 151 patients recruited and followed up these
patients until 72 months when the required 147 deaths had
accumulated.
As mentioned earlier, a trial conducted sequentially may or
may not be shorter than the trial based on a fixed sample size
design. The size and duration of a sequential trial are ran-
dom and depend on the size of the true treatment difference.
Table III shows expected sample size at termination for the
double triangular test under different magnitudes of the treat-
ment difference. Here and elsewhere in this section the word
'expected' is used in its technical statistical sense of an
TableII Anticipatedflowofinformationforthedoubletriangular test
used in the trial of chemotherapy and radiotherapy vs selective
treatment in the management of small-cell lung cancer
Months after Number of Number of Information
study opens patients deaths (V)
12 38 15 3.6
18 58 27 6.6
24 77 40 9.7
27 86 49 11.7
30 96 58 13.8
33 106 67 15.8
36 115 76 17.8
42 134 96 22.0
48 153 114 26.0
54 172 134 30.3
60 192 152 34.4
66 211 171 38.5
72 230 190 42.6
84 268 227 51.0
average value over many repetitions of the same investiga-
tion. It can be seen that when there is no treatment difference
(HR = 1), the expected number of deaths at termination is
98. When the real treatment difference is as anticipated
(HR = 0.586), the expected number of deaths at termination
is 90. When the anticipated improvement is only HR = 0.766,
the expected number of deaths is 109. These numbers are
well below 147, the number of deaths used in the conven-
tional design. Table III also shows the median and 90-th
percentile of the number of deaths. The median is the value
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Figure 1 a, The double triangular test with significance level = 0.05, power = 0.90 and HR = 0.586 used for the sequential
simulation of the MRC trial comparing ECMV vs ST in the management of small-cell lung cancer. b, Final plot of the sequential
simulation of the MRC comparison of ECMV vs ST in the management of small-cell lung cancer. c, Overrunning to 72 months of
the sequential simulation of the MRC comparison of ECMV vs ST in small-cell lung cancer. d, Sequential follow-up of the
accumulated data of the MRC comparison of ECMV vs ST in small-cell lung cancer.
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Table III Properties at termination of the double triangular test used in the trial of
chemotherapy and radiotherapy vs selective treatment in the management ofsmall-cell lung
cancer
Expected Median of 90-th percentile
Proportion Proportion number of number of ofnumber of
surviving surviving deaths deaths deaths
beyond beyond (Expected (Expected (Expected
Hazard 4 months 4 months duration duration, duration
ratio on ECMV on ST months) months) months)
1.705 0.31 0.5 90 (42) 84 (42) 142 (60)
1.306 0.40 0.5 109 (48) 104 (48) 159 (66)
1.000 0.50 0.5 98 (42) 92 (42) 135 (54)
0.766 0.59 0.5 109 (48) 104 (48) 159 (66)
0.586 0.67 0.5 90 (42) 84 (42) 142 (60)
exceeded with probability 0.5 and the 90-th percentile is the
value exceeded with probability 0.1. In the case of a modest
improvement even the 90-th percentile of the number of
deaths is not far above 147.
The maximum number of deaths required by the double
triangular test is 228 which corresponds to a value to
V = 57.04. According to Table II, it was to take at least 18
months before 10% of the maximum number of deaths was
accumulated (V = 5.7). The first interim analysis was
scheduled for December 1982, 18 months after the first
patient entry. The second one for June 1983, 6 months later,
and subsequent interim analyses 3-monthly thereafter.
Table IV shows the approximate P-value that would be
reported at the time of stopping, if superiority of the ECMV
treatment was discovered and the trial stopped, for selected
interim analyses. The P-value would be very small ifstopping
occurred at one of the early interim analyses.
Resultsfrom the sequential design
Points (V, Z) were plotted at each inspection to determine
when to stop the trial. According to plan, the first interim
look was performed 18 months after the first recruitment.
Patients alive at the time of analysis were considered cen-
sored at that time. A summary of the data accumulated at
this time is presented in the second part of Table I.
With these data a Cox's regression model was used to
investigate the relationship between survival time amd pos-
sible prognostic factors. Extent of disease (P = 0.0003) and
general condition (P = 0.007) were already apparent as
significant prognostic factors. All subsequent interim analyses
were stratified for both extent of disease and general condi-
tion, forming six strata in all. (The method of stratification is
explained in Whitehead, 1992, Section 7.2. Stratification is
easier to apply in sequential analysis than covariate adjust-
ment based on Cox's model, and does not depend on an
assumption of proportional hazards between strata.) The
sequential version of the trial ended at the seond interim
analysis with 94 patients recruited. The data summary is
presented in the third part of Table I.
Statistics Z and V obtained in the first two interim
analyses are plotted in Figure lb. The values were V = 8.3
and Z = 6.5 at the first look and V = 13.2 and Z = 10.1 at
the second. The dotted 'Christmas tree' boundary determines
stopping and corrects the original boundary, derived for
continuous monitoring, to allow for the gaps between looks.
The longer the gap, the narrower will be the Christmas tree
boundaries, making stopping easier in compensation for the
possibility of a missed opportunity of stopping between
looks. It is sufficient for stopping that the plotted point
reaches these inner dotted boundaries, as has occurred in this
case.
The null hypothesis was rejected, suggesting that there was
a significant beneficial effect of ECMV on survival. The
P-value allowing for interim looks at the time of stopping
was P = 0.008. The 95% confidence interval for the hazard
ratio was (0.28 , 0.82) and its estimate 0.47, all values allow-
ing for interim analyses. The estimate is median unbiased,
which is to say that it is smaller than the true population
Table IV P-value reported when crossing upper boundary of the
double triangular test used in the trial of chemotherapy and
radiotherapy vsselectivetreatmentinthemanagementofsmall-celllung
cancer
Time after P-value
Interim study opens adjustedfor
analysis (months) V previous looks
1 18 6.6 0.001
3 27 11.7 0.003
4 30 13.8 0.005
6 36 17.8 0.010
7 42 21.9 0.020
9 54 29.2 0.030
10 72 40.0 0.044
14 84 57.0 0.050
value with probability 1/2. With the data available at this
stage, the Kaplan-Meier estimates of the 4-month survival
rate, not allowing for previous interim looks, were 0.44 in the
ST group and 0.76 in the ECMV group. Estimates of the
4-month survival rates, brought closer together to allow for
the interim analyses, were 0.50 in the ST group compared to
0.70 in the ECMV group.
Incorporation offurther data
The principal analysis of a survival study rarely takes place
after all patients have died. Further deaths often occur after
the principal analysis has taken place, and further analyses
can then be performed. In the sequential design just des-
cribed, the power of 0.90 is achieved when the trial stops.
After the second interm analysis at 24 months, recruitment
would be closed. However, follow up data (and deaths)
would continue to be received. If the conduct of the trial
continues unchanged after recruitment has been closed, then
the new deaths reported during the subsequent follow up
period should be incorporated into the analysis. Often, ter-
mination of a trial and disclosure of its findings will affect
subsequent conduct and so the 'no change' assumption has
to be considered carefully. Here we imagine a further analysis
at 72 months, replacing that performed at 24 months. It
would be more powerful, and in the case of any discrepancy,
it would be definitive. The extra data collected after closure
of recruitment if referred to as overrunning, and the
methodology is discussed by Whitehead (1992b). Incorpora-
tion of the follow-up data up to 72 months after the trial
began from all 94 patients recruited before stopping occur-
red, produced a further 26 deaths and test statistic values of
V = 18.3 and Z = 12.0. The corresponding sample path is
shown in Figure lc. This leads to the same conclusion:
rejection of the null hypothesis in favour of ECMV. The
P-value was P = 0.014 and the 95% confidence interval for
the hazard ratio was (0.33 , 0.88) and its estimate 0.54.
Comparison with the actual trial
Had the sequential design been used and the trial stopped,
there would have been no further recruitment after 24SIMULATED SEQUENTIAL ANALYSIS 1175
months. In practice the trial was not stopped early, and we
are able to conduct the artificial but informative exercise of
continuing to plot points (V, Z) and displaying them on the
sequential diagram in order to compare the sequential with
the published analysis.
Figure ld shows how, after the second inspection, the
corresponding sample path would have stayed in the region
of rejection of no treatment difference in favour of ECMV.
Notice that this uses different data from Figure lc, as further
patients were recruited after the second look. It is not a
continuation of the previous sample path.
The comparative analyses presented in Table V show that
the conclusions of the trial at the time of stopping and after
overrunning were both in agreement with the trend exhibited
by the sample path when the trial was left to continue
beyond the second look until 72 months.
The P-value reported by the fixed sample analysis is
smaller. The estimate of the hazard ratio from the sequential
analysis is broadly similar to that from the fixed sample
study. The confidence interval was wider for the sequential
analysis but the upper limit was far below 1. This precision
was sufficient for the purpose of this research. There was no
need to look for a more accurate estimate of a large treat-
ment effect, especially when this involves further recruitment
of patients to a control treatment already shown to be
significantly inferior to the experimental treatment.
Table V also presents the substantial savings achieved by
the sequential design. Recruitment was stopped 24 months
after entry of the first patient and an analysis of the intended
power was then available. This effectively reduced the dura-
tion of the trial by 48 months. The reduction in the number
of patients and the actual number of deaths obtained even
allowing for a follow-up period of 72 months was still con-
siderable: 57 recruitments and 54 deaths.
Reanalysis of a clinical comparison of no-maintenance and
maintenance chemotherapy in the management of small-cell
lung cancer
This trial was designed to compare 12 against six courses of
the same chemotherapy in the treatment of small-cell lung
cancer, the patients with limited disease also receiving
radiotherapy to the tumour after the second course of
chemotherapy. All patients were prescribed initial treatment
with six courses of the ECMV regimen described in the
previous section for the first trial presented in this paper.
Patients with partial or complete response at the time of the
fifth course of initial chemotherapy were eligible for entry to
this trial. The random allocation was either to a further
six-course series of chemotherapy (M group) or to no further
maintenance chemotherapy (NoM group) (Medical Research
Council Lung Cancer Working Party, 1989b).
At total of 265 patients were recruited to this trial. Alloca-
tion to treatment was a randomised procedure stratified for
admitting centre, extent of disease (limited or extensive) pre-
treatment and degree of response (partial or complete) at the
time of randomisation. Maintenance chemotherapy started 4
weeks after the last course of the initial chemotherapy.
Subsequent courses were given at 4-week intervals.
Resultsfrom the completed trial
At 72-months from the date of start of chemotherapy,
follow-up to 36 months was complete for all 265 patients. In
all, 134 patients were allocated to the NoM-group and 131 to
the M-group. Of the 131 allocated to the M-group, 25%
never started maintenance chemotherapy. They were included
in the study in order to provide an intention-to-treat analysis.
Once more, the most important variables in predicting sur-
vival time were general condition at the time of randomisa-
tion (P = 0.001) and extent of disease was also important
(P = 0.01). After adjustment for these two factors, treatment
group had no significant effect on survival (P = 0.30). The
95% confidence interval for the ratio of hazard on the M
group to that on the NoM group was (0.67, 1.13) and its
estimate was 0.88. The median survival was 9 months in the
M-group and 7.5 months in the NoM-group. These results
agree with the results obtained by the Medical Research
Council Lung Cancer Working Party (1989b). No justi-
fication for the trial size was included in the trial protocol or
the published report.
Choice of a sequential design
Among the sequential stopping rules appropriate for this
trial, the single triangular design was chosen on the basis of
its asymmetric power requirement and minimum sample size
considerations (see Whitehead, 1993). Asymmetric designs
require a high probability to detect superiority of the experi-
mental treatment while the probability to detect its inferiority
is relaxed. This seemed appropriate in this trial: it was impor-
tant to produce conclusive evidence of superiority of addi-
tional maintenance chemotherapy (M) if it was indeed
effective. However, if it was ineffective, it was less important
to prove this. Given its toxicity, clinicians would only choose
to use M if it were superior.
The triangular design would lead to stopping the study if
either a striking advantage for the M group became appar-
ent, or if no advantage emerged. The rapid result in the case
of no advantage, allowing recruitment to M to be closed, was
important given the toxicity of the chemotherapy. In the case
of a moderate improvement in survival due to maintenance
chemotherapy, the design guaranteed a larger sample size,
which was then desirable to obtain a more reliable estimate
of the treatment difference. This larger sample size was none-
theless very likely to be smaller than that of a conventional
design.
The triangular test was designed to detect a difference
between the treatments measured in terms of improvement in
survival on M chemotherapy compared with NoM. The
analysis performed by the MRC took place when 235 deaths
had accumulated. The median survival in the NoM group
was anticipated to be 8 months. To make the sequential
study comparable, it was assumed that the aim of the trial
was to give a 90% chance of detecting as significant at the
5% level (two-sided alternative) an increased 8-month sur-
vival to 0.64 in the M group. Such a treatment difference
corresponds to a hazard ratio (M relative to NoM) of
HR = 0.66.
Statistics Z and V described in the previous section were
used. Assuming a recruitment rate of six patients per month,
and interpolating the expected 32-week survival probabilities
exponentially, it was anticipated that the required 235 deaths
would accrue in 72 months. The design is shown in Figure 2a.
It can be seen from Table VI that the expected sample size
under different magnitudes of treatment difference is well
below 235, the number of deaths used in the conventional
study. In the case of a modest improvement even the 90-th
percentile of the number of deaths is not far above 235. The
Table V Analysis, estimation, size and duration at termination of the trial of chemotherapy and
radiotherapy vs selective treatment in the management of small-cell lung cancer
Median unbiased 95% C.L. Duration Number Number
estimate ofHR for HR P-value (months) deaths patients
Sequential 0.47 (0.28,0.82) 0.008 24 67 94
Overrunning 0.54 (0.33,0.88) 0.014 72 93 94
MRC procedure 0.44 (0.30,0.64) <0.001 72 147 1511176 A.N. DONALDSON et al.
maximum number of deaths was 363, although continuation
to this value is of negligible probability. Anticipating approx-
imately ten looks as in the previous trial, the first interim
look was scheduled for December 1982, 18 months after the
first recruitment and subsequent looks at 6-month intervals.
Resultsfrom the sequential design
Points (V, Z) were plotted at each inspection to determine
whether to stop the trial. At the first interim look, no prog-
nostic factors were detected to have a significant relationship
with survival. A survival analysis, stratified for the extent of
disease pre-treatment and degree of response at time of ran-
domisation was used. These factors were allowed for when
allocating patients to treatment, and so all analyses are
adjusted for them.
The trial ended at the third interim analysis. The sample
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path is shown in Figure 2b. The trial concluded with accep-
tance of the null hypothesis, suggesting that there is no
evidence that survival can be prolonged by a policy of con-
tinuing chemotherapy beyond the initial induction treatment
of six courses. The P-value at the time of stopping was
P = 0.44, the 95% confidence interval for the hazard ratio
was (0.77, 1.06) and the median unbiased estimate was 1.19.
All of these values allow for the previous interim analyses.
Following the method described in the previous example, late
results gathered from a follow up to 72 months were incor-
porated in the analysis, and a comparison with the sample
path which would have emerged had the trial not been
stopped is made. The results are shown in Figures 2c and d,
and in Table VII.
The conclusions of the trial at the time of stopping and
after overrunning are both in agreement with the trend
exhibited by the sample path when the trial was left to
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Figure 2 a, The triangular test with significance level = 0.05, power = 0.90 and HR = 0.655 used for the sequential simulation of
the MRC trial comparing maintenance vs non-maintenance chemotherapy in the management of small-cell lung cancer. b, Final
plot of the sequential simulation of the MRC comparison ofmaintenance vs non-maintenance chemotherapy in the management of
small-cell lung cancer. c, Overrunning to 72 months of the sequential simulation of the MRC comparison of maintenance vs
non-maintenance chemotherapy in the management of small-cell lung cancer. d, Sequential follow-up of the accumulated data of
the MRC comparison of maintenance vs non-maintenance chemotherapy in the management of small-cell lung cancer.
Table VI Properties at termination of the triangular test for the trial of maintenance vs
no-maintenance chemotherapy in small-cell lung cancer
Proportion Proportion
surviving surviving
beyond beyond Expected Median of 90-th percentile
Hazard 8 months 8 months number of number of ofnumber of
ratio (M group) (NoM group) deaths deaths deaths
1.236 0.430 0.5 78 73 117
1.000 0.500 0.5 117 108 189
0.809 0.570 0.5 168 164 254
0.655 0.635 0.5 142 133 227SIMULATED SEQUENTIAL ANALYSIS 1177
Table VII Analysis, estimation, size and duration at termination of the trial of maintenance vs
no-maintenance chemotherapy in small-cell lung cancer
Median unbiased 95% C.L Duration Number Number
estimate ofHR for HR P-value (months) deaths patients
Sequential 1.19 (0.77,1.82) 0.44 27 92 180
Overrunning 1.01 (0.69,1.43) 0.97 72 172 180
MRC procedure 0.88 (0.67,1.13) 0.30 72 255 265
continue beyond the third look until 72 months. The P-value
reported by the MRC procedure was larger than that of the
sequential analysis. The estimate of the hazard ratio from the
sequential analysis is broadly similar to that from the fixed
sample study. The confidence interval is wider for the sequen-
tial analysis but clearly covering one. This situation was also
sufficient for the purpose of this trial: there was no need to
recruit more patients to look for a more accurate estimate of
a small treatment effect. Table VII also shows the substantial
reductions brought by the sequential design. Recruitment was
stopped 27 months after entry of the first patient and an
analysis was produced. A reduction in the duration of the
trial by 45 months was achieved. The reduction in the
number ofpatients and the actual number of deaths obtained
after a follow-up period of 72 months was also considerable:
85 recruitments and 83 deaths.
Discussion
The comparative reanalyses performed for each of the two
trials considered here show that the qualitative conclusions of
significance were in agreement with one another. The sequen-
tial designs were completed more quickly and with fewer
patients, whereas the MRC procedures achieved smaller P-
values. Estimates of hazard ratios from the sequential designs
were broadly similar to those from the MRC procedures,
especially when overrunning was allowed. Confidence inter-
vals from the sequential analyses are in general wider than
those from fixed-sample analyses. In our reanalyses, the
confidence intervals were wider in the sequential analyses
even when overrunning was allowed. This situation was
acceptable since there was no need to look for a more
accurate estimation of a clearly large or small treatment
effect, and therefore it was unethical to continue recruitment
for this purpose. Of course, these comments apply to only
two illustrative trials. Their general validity however follows
from mathematical results presented in Whitehead (1992).
Both the triangular and the double triangular tests illus-
trated here were chosen under the assumption that the single
end-point, duration of survival, was of principal interest. If
secondary end-points such as those indicating quality of life
are also going to be important in the final analysis, then a
sequential design might be chosen which ensures that a
relatively large sample is observed unless a major treatment
difference becomes apparent. One such design is the restricted
procedure (see Whitehead, 1993). In the second trial present-
ed in this paper, quality of life endpoints were of interest in
addition to survival. The relative merits of different sequen-
tial designs would have needed careful consideration had the
trial been planned according to the methods of this paper.
It has to be admitted that our reanalyses were idealised in
that all events occurring before 18 months, say, were
included in the interim analyses conducted at 18 months. In
practice there would be a reporting lag. However, manage-
ment procedures could be instituted to maximise the
information available at the time of each interim analysis.
Furthermore, in retrospect it was difficult to know what
planning predictions would have been made about recruit-
ment rate, and hindsight based on the real trial results
influenced the predictions which we used. Note however, that
such predictions effect only statements about the likely dura-
tion of the study. If the predictions are wrong, the study
design and analysis remain valid and the power is achieved.
It just might take longer (or shorter) to complete the trial
than had been first thought.
Although any sequential procedure requires a commitment
to accumulate a sample size larger than that of the fixed
sample design, these trials both reached a conclusion before
the available information has been used up. The conclusions
of the trials at the time of stopping and after overrunning
have been in agreement with the trend exhibited by the
sample path when the trial has been followed beyond the
final look up to the time of the fixed-sample analysis.
Formal stopping rules have been taken up by the phar-
maceutical industry in Europe and by the National Cancer
Institute in the United States. The methodology has so far
been applied to many studies, some of them involving lung
cancer, leukaemia, stroke and respiratory distress in infants.
A sequential design has been adopted by the Medical
Research Counceil Urological Working Party: Renal Car-
cinoma Subgroup for a phase III study comparing the effect
of a biological (a-Interferon) vs a hormonal (medroxy-
progesterone acetate) therapy in the management of renal
carcinoma (MRC Urological Working Party, 1991).
This work has been completed under Grant NO. G9008019 from the
British Medical Research Council. The authors would like to thank
the MRC Lung Cancer Working Party, for making the data
available and for their interest and cooperation in this project. Also
we are grateful for helpful comments made on earlier drafts by Dr
D.J. Girling, Dr. M.K.B. Parmar, Professor N.M. Bleehen and
Professor R.L. Souhami.
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